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Title 
The experiences of the community pharmacy team in supporting people with dementia and 
family carers with medication management during the COVID-19 pandemic. 
Abstract 
Background: The novel coronavirus COVID-19 pandemic has changed the lives of people 
across the globe in significant and long-lasting ways. People with dementia were 
significantly and disproportionally affected at the height of the pandemic in England. 
Community pharmacies in England continued to operate during the pandemic but had to 
adjust the way they provided key healthcare services. The impact of these changes on the 
provision of medication services to people with dementia is underexplored.  
Objective: To explore the experiences of the community pharmacy team in supporting 
people with dementia and family carers manage medications during the COVID-19 
pandemic.  
Methods: An interpretivist/constructivist research paradigm was used; semi-structured one-
to-one telephone interviews were conducted with any member of the community pharmacy 
team who had been involved in providing medication services to people with dementia in 
England before and during the COVID-19 pandemic. Recruitment took place between July 
and August 2020. Interviews were audio-recorded, transcribed verbatim and analysed using 
thematic analysis.  
Results: Fourteen participants were interviewed with equal numbers of qualified 
pharmacists and non-pharmacist staff. Participants were in their role for an average of 4.5 
years. The analysis of interviews generated three themes: 1) key interactions curtailed due 
to COVID-19 restrictions, 2) utilising resources within and outside of the pharmacy to 
provide tailored services for people with dementia, and 3) the interplay between 
professional duty and personal values underpinned decisions to provide medication 
services.  
Conclusions: The study provided a unique and important first insights to our understanding 
of how the community pharmacy team in England supported people with dementia and 
their family carers during the COVID-19 pandemic. These insights provide opportunities for 
reflection by individuals, healthcare teams, healthcare organisations, policy makers and the 
public, in an international context, to enable long-term planning, investment and 
implementation of strategies beyond the current pandemic. 
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Introduction  
The novel coronavirus COVID-19 pandemic has changed and is continuing to change the 
lives of people across the globe in significant and long-lasting ways. At the time of writing, 
around 35 million cases of COVID-19 infections have been reported and more than 1 million 
people have died because of COVID-19, worldwide1. It has been ten-months since the novel 
coronavirus was first identified in Wuhan, China and seven-months since the World Health 
Organisation (WHO) declared a global pandemic2 – the world is still learning about this novel 
virus and the end of the pandemic is not yet in sight with a resurgence in some countries3. 
Governments and healthcare systems across the world are responding to the novel COVID-
19 pandemic in different ways.  
 
In the United Kingdom (UK), the rate of infection was increasing between 5-9% per day at 
the time of writing4. The focus of the English government continues to be on reducing virus 
transmission. At the height of the COVID-19 pandemic in England, restrictions such as 
‘shielding’ (not leaving their homes and minimise contact with others) clinically extremely 
vulnerable people, social distancing (maintaining two metres distance between individuals) 
and self-isolation were in place. These restrictions affected the general population and some 
vulnerable groups such as people with dementia were significantly and disproportionally 
affected5. Dementia was the most common pre-existing condition for COVID-19 deaths in 
England and Wales accounting for 25.6% of deaths6. More than 90% of people with 
dementia have at least one other health condition7 and are at higher risk from COVID-19.  
This meant that many people with dementia, of which around 61% live at home8 and 1/3 
live alone9, were house bound. For many people with dementia, medications are a key part 
of daily living. Managing medications is complex and multifaceted10-11 and can lead to 
medication errors and medication-related hospital admissions12. Therefore, it is important 
to ensure that the system of managing medications is robust and fit for purpose. During the 
pandemic, however, many people with dementia were not able to access medications as 
they would normally.  
 
Community pharmacists in the UK continued to operate during the pandemic. With around 
1.6 million visits to community pharmacies per day in England alone13, they are one of the 
most easily accessible healthcare professionals providing a key health service to the 
population. Spaces within community pharmacies enables multiple functions and complex 
interactions to take place with the public, providing opportunities to support the health and 
wellbeing needs of the general population. However, during the pandemic, community 
pharmacies had to adjust the way they used such spaces and how they provided key 
healthcare services. The impact of these changes on the provision of medication services to 
vulnerable patient groups such as people with dementia was unknown.  
 
Aim  
To explore the experiences of the community pharmacy team in supporting people with 




This qualitative study is reported using COREQ14. 
 
Research team and reflexivity 
The research team consisted of two undergraduate female Master of Pharmacy students 
(RS, BK) and a female academic pharmacist with a doctorate and experience of qualitative 
research methodology (RL). RS was trained by RL and conducted all the interviews. BS was 
trained by RL and undertook the analysis of the interviews.  
 
Participant selection 
Purposive sampling was used to recruit participants via key contacts within RL’s existing 
networks using email, social media (Twitter and Facebook) and word of mouth. RL emailed 
key contacts with the study invitation letter, participant information sheet and consent 
form. They then sent out information about the study via email to their own networks. The 
inclusion criteria were any member of the community pharmacy team who were over the 
age of 18 years old and had been involved in providing medication services to people with 
dementia in England before and during the COVID-19 pandemic. Recruitment took place in 
July and August 2020 until a maximum of 15 participants had been interviewed. The focus 
was on the ‘depth/richness’ of data collected rather than the breadth (e.g. existence of new 
information). Informed consent was given prior to interviews. 
 
Study design 
An interpretivist/constructivist paradigm underpinned the design and conduct of this 
study15; people who work in the community pharmacy have different experiences of 
supporting people with dementia/carers. Phenomenology as a methodology was used to 
explore and understand unique participants’ experiences using semi-structured one-to-one 
interviews.  Researchers actively encouraged discussions emphasising the uniqueness of 
participants’ experiences and constructed meaning from interview data shaped by their own 
personal perspectives.  
 
Setting 
Interviews were conducted over the telephone by a single researcher (RS) at a time that 
suited the participant.  
 
Data collection  
One-off one-to-one semi-structured interviews were conducted over the telephone. 
Interviews explored 1. The range of services provided to people with dementia/family carers 
and the general aim of these and, 2. Two examples of service provision (one pre- and one 
during the COVID-19 pandemic): the general circumstances leading up to the example given 
(individual, team, ward and organisational levels), action taken (how, why, when, where), 
facilitators and barriers to performing task, informed by the Critical Incident Technique16. 
Demographic data such as age, gender, years in practice/role, type and location of practice 
were also collected to describe the sample of participants. The interview schedule was 
piloted several times within the research team and changes made to the interview schedule. 
See Box 1 for the final version of the interview schedule. All interviews were audio-recorded 
with consent from participants and then transcribed verbatim by BK onto Microsoft Word 
documents. Every transcript was checked against the corresponding audio-recording for 
accuracy. Any identifying information was removed at the point of transcription.    
Box 1: Interview schedule 
General demographic questions 
• Can I ask what your role is in your pharmacy? Tell me a little about that. 
• How long have you been in your current role? 
• How would you describe the environment in your pharmacy is like on a daily basis? 
(before and during the pandemic) 
 
Range of services and general aim  
• On average, in a week, how many people with dementia or their carers do you meet? 
(before and during the pandemic) 
• We are interested in the types of medication services that you provide for people with 
dementia, living in their own home. Can you describe to me these types of services? 
 
Example before COVID-19 
I am very interested to find out what life was like before the pandemic, in terms of the 
medication services that you provided for people with dementia.  
• Can you go back to before the pandemic happened and recall a specific example of a 
time you provided a medicine service for a person with dementia. Talk to me about 
the experience in as much detail as you can.  
Prompts: regular basis, when needed, how the service was developed, what helps, 
teamwork, feedback regarding service 
 
Example during COVID-19  
Now using this same exact service, were you able to provide this service or not since the 
pandemic started?  
• If they haven’t been able to provide the service,  
Prompts: how do you feel about not being able to do so? What do you think needed to 
happen for you to be able to do it? 
• If they continued to be able to provide the service,  
Prompts: what changed from the last time you provided it? If anything? What helped you 
provide this service? How has the team around you contributed to it? Also, here, any 
feedback or way of monitoring? 
 
Generally, what changes (if any) have you incorporated into the workplace for people 
with dementia during the pandemic? 
 
What else could have been done differently? What do you think might/would help you do 
better in providing these services? 
 
If a second wave was to hit, do you think you will be prepared for it? Are there any 
preparations made for you to do your job safely?  
 
Is there anything else you would like to add to what we have just discussed?  
 
 
Data analysis  
Interviews were analysed using inductive thematic analysis17. Guided extensively by RL, an 
experienced qualitative researcher, BK analysed the interview data. BK familiarised herself 
with the interview data through the transcribing of the audio-recordings, reading and re-
reading the interview transcripts. Using NVivo 1218, BK then undertook line-by-line coding of 
each interview transcript. Initial themes were generated and then reviewed against the 
interview dataset. Following further refinement of themes, BK developed a detailed analysis 
of each theme. The analysis process was iterative and multiple discussions were held 
between BK and RL at each stage of the analysis to guide the analysis process, not to 
achieve consensus on the interpretation of interview data.  
Results 
Participant demographics 
A total of 14 participants consented and took part in the interview study. Interviews took 
place between July and August 2020. Due to the way in which recruitment was conducted, it 
was not possible to ascertain the number of people whom the study invitation may have 
reached. Recruitment stopped when there was sufficient depth/richness to the data. Table 
1 shows the demographic data of participants. Most participants were female (n=10, 71%) 
and half were under 30-years old.  There were equal numbers of qualified pharmacists and 
non-pharmacist staff who took part in the study. Half of the participants worked in 
independent pharmacies. Pharmacies where participants worked were mostly concentrated 
in the South East of England (see Figure 1). Participants were in their current role between 4 
months and 13 years (mean = 4.5 years).  Interviews with participants lasted between 18 
and 38 minutes (mean = 29 minutes). 
 
Table 1 Demographic data of participants (n=14) 
Gender 
Male 4 (28.6%) 
Female 10 (71.4%) 
Age 
18-29 years 7 (50%) 
30-39 years 4 (28.6%) 
40-49 years 3 (21.4%) 
Role in the pharmacy 
Pharmacy dispenser 5 (35.7%) 
Pharmacy technician 1 (7.1%) 
Pre-registration pharmacist 1 (7.1%) 
Pharmacist 7 * (50.0%) 
Time in post  
0 to 1 year 5 (35.7%) 
2-5 years  5 (35.7%) 
6-13 years 4 (28.6%) 
Ownership of pharmacy 
Independent 7 (50.0%) 
Part of a chain 6 (43.0%) 
Independent and part of a chain 1 (7.0%) 
*5 store pharmacist/pharmacist manager, 2 long-term locum pharmacist 
 
Figure 1: Location of the pharmacy where participants’ worked. 
 
Medication services provided for people with dementia  
Before the COVID-19 pandemic, the range of medication services provided for people with 
dementia included compliance aids (for example, dosette boxes, blister packs and 
monitored dosage systems), medication administration records (a document used to record 
the administration/taking of medication), medication home delivery services, Medicines Use 
Reviews (structured medication reviews with patients taking multiple medications), New 
Medicines Services (support with taking a new medication), repeat dispensing service 
(dispense repeat dispensing prescriptions issued by a General Practitioner), minor ailment 
scheme (advice and treatment for some common illnesses) and the flu vaccination service. 
Most of these services are funded by the National Health Service (NHS) whilst others such as 
medication administration records and medication home delivery services are not. 
Pharmacy teams prioritised the provision of medication services that they considered to be 
essential during the pandemic such as compliance aids, medication administration records 
and medication home delivery services. Services that typically required face-to-face contact 
such as the Medicines Use Reviews and New Medicines Services were paused.  
 
Qualitative findings 
The analysis of interviews generated three themes: 1) key interactions curtailed due to 
COVID-19 restrictions, 2) utilising resources within and outside of the pharmacy to provide 
tailored services for people with dementia, and 3) interplay between professional duty and 
personal values underpinned decisions to provide medication services. 
 
Key interactions curtailed due to COVID-19 restrictions 
The COVID-19 restrictions relevant to the study context included the use of personal 
protective equipment (PPE), social distancing measures (2 metres between individuals) and 
the ‘shielding’ of vulnerable individuals (a measure to protect people at high risk from 
COVID-19 by staying at home and avoiding all face-to-face contact. This ended on the 1st 
August 2020 in England). The critical aspect of social interaction for people with dementia 
was not possible. People with dementia who wanted to collect their medication were 
unable to do so because they were ‘shielding’. Some pharmacies spent time finding out the 
personal circumstances of people with dementia, whether they had someone who could 
collect medications on their behalf. For many, pharmacies started delivering medications to 
the people’s homes. The reduction in face-to-face contact also meant that pharmacy teams 
were unable to have the same level of interaction with people with dementia with regards 
to their medication. Maintaining independence and autonomy over medications were 
challenged. 
 
“…even the ones that wanted to collect but that was their independence and they 
quite like coming into the shop seeing us, they had to shield.” Participant 10 
 
“The patients that we did see with dementia [before the pandemic], we don’t see 
them at all. The communication itself with them is a lot harder. We tend to see their 
family more than the patient themselves.” Participant 1 
 
For people with dementia who usually have their medications delivered, the social 
distancing measures also impacted negatively on the interaction that they had with the 
pharmacy delivery driver. This posed challenges in identifying important cues from people 
with dementia.  Pharmacy teams were faced with difficult decisions, balancing the COVID-19 
restrictions and providing high quality care.  
 
“…you’re now having to arrange deliveries in such a way that it’s observing social 
distance so where our delivery driver would typically have, know quite a lot of the 
patients because of the interactions she has with them, that has stopped purely 
because now having to observe the 2 meters. There’s minimal kind of communication 
so you’re not getting as much information indirectly from the patients during the 
interactions. So, I think that’s definitely a small part of it but it’s overlooked because 
you quite often get a lot of information from how patients are doing in that way.” 
Participant 8 
 
Utilising resources within and outside of the pharmacy to provide tailored services for 
people with dementia 
 
The importance and value of teamwork was amplified during the time of the pandemic. 
Each pharmacy team member had specific skillsets; these were acknowledged even before 
the pandemic and used collectively to benefit the pharmacy team and patients. The teams’ 
previous experiences with people with dementia meant that they were confident in 
providing services both prior to, during and if there was a resurgence of the pandemic.  
 
“So, I’d say it’s probably a build-up of experience and understanding systems that are 
available to us. So, understanding that you know, there are dosette boxes, there are 
MAR charts, there are patient contacts, Dementia Friends. I think it’s just a build-up 
of information and build-up of experience. I think like 5 years ago, I probably 
wouldn’t have dealt with it so well, if I’m honest.” Participant 12 
 
Pharmacy team members worked together to ensure that patients received their 
medication; many worked overtime to clear prescription back-logs and to ensure that staff 
on the next day were able to focus on the day’s work.  
 
“…we stayed until about 2 am, trying to catch up from a back log because at one 
point they were, I think we were like five days behind on prescriptions. So, me and my 
senior dispenser there stayed until 2 am trying to catch up some of this crazy back log 
and hopefully set the weekend staff up with, you know, something that was a bit 
more manageable.” Participant 5   
 
Pharmacies made difficult trade-offs during the pandemic. Not all services continued during 
the pandemic. For example, pharmacies were asked not to continue to provide medication 
in compliance aids; some were able to continue with the service whilst others did not. 
  
“…we were given the alternative from NHS England that we could, rather than do the 
dosette tray, we could just send the MAR chart out with the boxes in 28, you know in 
their normal dispensing pack. But we, myself and my dispenser, made a decision that 
we would carry on supplying the dosette boxes. Their thinking was, if we all got ill 
with COVID, the dosette boxes are quite time consuming and it was to reduce the 
workload but we felt, especially patients with dementia, they got used to that 
system, and then to go and change it, wouldn’t be very fair on them and cause 
anxiety. So, we decided to keep it as it was, so that…simple as it could be for those 
dementia patients.” Participant 6  
 
“…doing the trays, the dosette boxes [compliance aids] and we did have to cut that 
out unfortunately. It was part of company protocol. Just quite unfeasible.” 
Participant 14 
 
Pharmacies drew on external help to provide services to people with dementia. NHS 
England/Improvement provided crucial funding to enable pharmacies to provide home 
medication delivery services, that would otherwise be financially unsustainable. Pharmacies 
also accessed support from volunteers that were part of the NHS Volunteer Responders 
programme that was set up to support the NHS and social care sector during the pandemic. 
These volunteers delivered medication to people’s homes.   
 
“That [funding] also allowed us to extend the service to I suppose to those patients 
who we wouldn’t have delivered for. Because we were having to scale back on 
deliveries anyway prior to, so that only picked up as a result of the funding that went 
into pharmacies for this pandemic specifically.” Participant 8 
 
“…it was just incredibly crazy you know, everybody just needed their prescriptions 
delivered. So, it was very hard but we had to rely on extra support from these NHS 




Interplay between professional duty and personal values underpinned decisions to 
provide medication services. 
Although many pharmacies are renumerated under the Pharmacy Quality Scheme when 
they complete the Dementia Friendly Environment Checklist and undertake training to 
become Dementia Friends, many focused on building relationships with people with 
dementia and their family. It is the rapport, trust and understanding of the person’s 
circumstances that underpinned their decision-making in the provision of medication 
services before and during the pandemic.  
 
“…we flag it up if someone’s got dementia so we know like if they’re ringing us or 
that we can help them. So, we know our customers that need more help than others, 
so like on a personal basis so I guess that’s how we try and help them.” Participant 2 
 
Pharmacy staff were willing to meet the needs of individuals even in very unusual situations, 
at the pharmacy/their own expense.  The interplay between professional duties/role and 
personal values appears to be the catalyst for decision-making relating to the provision 
medication services. 
 
“Obviously, I’m sure that you’re aware that that’s not possible and that we couldn’t 
source that [five-compartment compliance aid] from anywhere. So, we have to make 
the four-compartment tray, the usual one and then we have to cut up an extra one 
and cellotape it on. It’s because that that patient is so into their disease progression 
that they need that extra one, so we make a five one. Five-compartment one 
ourselves.” Participant 4 
 
“There was one in particular and she [person with dementia] lives in sheltered 
accommodation, but she doesn’t have any family, and one of medicine counter 
assistant took around her prescription for her, because she only lives around like the 
corner to walk there and it came down on a Friday when we didn’t have a driver” 
Participant 7  
 
Discussion  
This study provided a unique and possibly the first view on the experiences of the 
community pharmacy team in providing medication services to people with dementia and 
their informal carers prior to and during the COVID-19 pandemic, within an English context. 
Our principal findings were that key face-to-face interactions with people with dementia 
stopped during the COVID-19 restrictions but pharmacy teams drew extensively from 
internal (pharmacy/personal) and external (government) resources and negotiated 
professional decision-making and personal values to provide essential medication services 
to people with dementia.  
 
In the early stages of the COVID-19 pandemic in England, face-to-face interactions were 
restricted because many people with dementia were ‘shielding’, following government 
guidelines. Community pharmacy teams were able to adapt very quickly to the immediate 
needs of people with dementia, for example, in providing medication home delivery 
services, with additional funding from NHS England. Other key aspects of medication 
management for people with dementia, however, must not be neglected during a 
pandemic. Key aspects such as discussions about concerns relating to medications and 
regular monitoring to ensure medications are still being used appropriately are important 
not only to ensure medication safety but also to maintain/develop trust between the 
community pharmacy team and the person with dementia/informal carer. Alternative 
methods to communicating face-to-face such as telephone and video-consultations could be 
viable options19-22 to complement and not replace face-to-face communication. The needs 
of the pharmacy, pharmacy team, people with dementia and their informal carers, however, 
will need to be considered before adoption. How would the person with dementia respond 
to speaking on the telephone or video-call? Are video-conferencing facilities available, and if 
they are, what are the training needs for the pharmacy team and people with 
dementia/informal carers who may not routinely use this form of technology. These are not 
insurmountable issues but will require careful consideration in close collaboration with 
people with dementia and their informal carers and additional funding. It is important to 
ensure that the needs and voices of people with dementia and their carers are heard and 
addressed23 to ensure that safe and effective provision of services. Working with third 
sector organisations that advocates for people with dementia for example, the Alzheimer’s 
Society in the UK and Alzheimer’s Association in the US, can facilitate effective partnerships 
between patient groups and care providers.  
 
Teamwork was key in enabling participants to provide crucial medication services to people 
with dementia, and consistent with Salas et al.’s 24 model of five key dimensions of effective 
teams. For example, team leadership that extends beyond coordination and planning, and 
includes development of the team in utilising the complementary skillsets, knowledge and 
experience of the pharmacy team was evident. Participants also described teams that were 
sensitive to the needs and strengths of individual team members culminating in proactive 
support of each other. The adaptive capacity of participants and their teams, for example, in 
switching to home delivery, providing a five-compartment dosette box to mention a couple, 
was important to ensure that people with dementia continued to receive support with their 
medication. It was also clear that participants worked as a team and these teams shared the 
same goals of wanting to care for people with dementia as best they can given the COVID-
19 restrictions. There was mutual trust and respect for members of the team. Effective 
teamwork has been associated with safe and effective care25-28 and especially important 
when caring for vulnerable groups of patients such as people with dementia who may 
require additional help.  Developing effective teams is not easy and requires investment and 
interventions targeted at individual, team and organisational levels29. With increasing 
efforts to work in partnership/close collaboration with people with dementia and carers in 
research30, it is prudent to consider if, how and to what extent the ‘team’ in a community 
pharmacy setting could extend beyond pharmacy staff to include people with dementia and 
carers, and other healthcare professionals within an inter-professional healthcare context.  
 
Implications for practice and future research 
COVID-19 has highlighted potential areas for long-term planning and investment necessary 
for resilient provision of medication services for people with dementia within the 
community pharmacy setting. Firstly, community pharmacies can explore opportunities to 
work closely with people with dementia/carers to design services that are safe and 
effective. Working with local patient groups is a good starting point.  Secondly, the use of 
technology in supplementing face-to-face interactions warrants further consideration and 
research. A Human Factors and Ergonomics (HFE) design approach that emphases a user-
centred, whole systems view is highly recommended in analysing, designing, and 
implementing technological solutions31. The HFE approach emphasises meaningful 
collaboration with people with dementia/carers as users of services. Participants 
emphasised the importance of teamwork and there are also opportunities for HFE experts 
to work with community pharmacy teams, people with dementia and carer and the wider 
inter-professional healthcare professional teams to enhance and/or develop teamwork 
focusing on non-technical skills (interpersonal skills including cognitive and social skills)32. 
Finally, it is important to have a long-term view when developing and refining medication 
services rather than introducing short-term solutions that may not be sustainable and 
resilient over time. The concept of Resilient HealthCare (RHC)33 that is gaining traction 
amongst safety and clinical researchers could be explored and applied in this setting. There 
are increasing efforts to study RHC and identify ways to develop and enhance RHC such as 
effective team relationships, trade-offs and ‘resilience’ training of health care professionals, 
that can be drawn upon34.  
 
Strengths and limitations 
Empirical research on the experiences of the community pharmacy team in providing 
medication services to people with dementia and their carers in England during the COVID-
19 pandemic is scarce. This original study provided new insight to our understanding of their 
experiences during a significant time-point during the pandemic. During the time of writing, 
there is a resurgence of COVID-19 in England and some countries worldwide. The work 
presented in this study will be of relevance to countries across the world during and beyond 
COVID-19, where community pharmacies play an important role in providing crucial 
medication services to people with dementia. For example, the involvement of people with 
dementia and carers in the design and provision of medication services, careful 
consideration of the use of technology to enable rather than hinder and realising the 
benefits of effective teamwork in better patient outcomes. 
An interpretivist/constructivist paradigm was used to understand the experiences of the 
community pharmacy team and as such, the findings were shaped by the researcher’s 
personal experiences. A different research paradigm such as grounded theory may derive 
different meanings from the interview data. Although the student researchers were new to 
qualitative research, they were guided extensively by the research supervisor at each stage 
of the research process. Participants were an opportunistic sample and willing to discuss 
their experiences openly and in-depth. Therefore, there may be a tendency and bias 
towards expressing positive experiences. Participants recalled their personal experiences 
providing medication services to people with dementia prior to and during the pandemic. 
Their recall of specific examples of medication provision, guided by our interview questions, 
may be subject to recall bias and may not accurately reflect what happened. Nevertheless, 
the study aimed to construct a view of the experiences of the community pharmacy team, 
and not individual experiences. 
 
Conclusion 
The study provided a unique and important first insights to our understanding of how the 
community pharmacy team in England respond to the COVID-19 pandemic, specific to the 
provision of medication services to people with dementia and their informal carers. The 
implications of the study extend beyond the current pandemic and the English context to 
provide opportunities for reflection by individuals, healthcare teams, healthcare 
organisations, policy makers and the public, to enable long-term planning, investment and 
implementation of strategies. 
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